Franck Latrille

Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland.

NextPharma Technologies Holding Ltd. operates as a pharmaceutical contract development and manufacturing firm. It specializes in modified release technologies and in product manufacturing including hormones, penicillin, and cephalosporin. The company was founded on January 2, 2003 and is headquartered in London, the United Kingdom.

NextPharma Technologies, In. develops, manufactures, packages, and distributes pharmaceutical products and formulations. The firm focuses on lyophilization, sterile fill finish and pellet technologies, and in product manufacturing including cyotoxics, hormones, penicillins, cephalosporins, and controlled drugs. The company was established on October 27, 2000 and is headquartered in London, the United Kingdom.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.